Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
This Month's Featured News
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Authored by Jeffrey Neal Johnson. Publication Date: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
SpaceX is targeting a $1.75 trillion valuation in what could be the largest IPO in market history - bigger than Saudi Aramco, bigger than Alibaba. The confidential S-1 is expected next month, with the offering slated for June.
One chokepoint company powers the infrastructure Musk can't build around. When the prospectus drops, most investors will already be behind. Get the company name before the S-1 hits the market
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A deeper look into Abbott’s situation reveals a potential disconnect between market sentiment and operational reality, raising a critical question: Is the market’s pessimism justified, or has a meaningful value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason. The recent decline stems from two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott’s fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, primarily due to market-share losses in its U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described pricing and promotion initiatives and a pipeline of at least eight new product launches in 2026 to reignite volume growth, forecasting a return to growth in the second half of the year. The second factor is external and broader in scope. The market has been undergoing a significant rotation of capital: in periods of economic optimism, investors often move funds away from stable, defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in pursuit of faster returns. That broad market trend has applied pressure to many fundamentally sound healthcare stocks, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott’s core remains exceptionally strong, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in Nutrition, and the company’s health is most apparent in these high-performing areas.
Medical Devices: The Medical Devices segment is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) remains a growth phenomenon. This product line, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and is a primary driver of Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. That strength comes from a portfolio of best-in-class products, such as MitraClip and TriClip, which offer minimally invasive solutions for valve repair, and a pipeline of innovations including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning itself for future growth through the acquisition of Exact Sciences, a leader in cancer screening and diagnostics best known for its non-invasive colon cancer test, Cologuard. The deal would immediately place Abbott as a major player in the rapidly expanding cancer diagnostics market, adding a new, high-growth vertical with multi-year revenue potential. That bullish view is reflected by analysts. Wall Street maintains a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying potential upside of more than 30% from current levels and suggesting many see the shares as undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a standout feature. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep-seated commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current prices, Abbott yields about 2.5%, allowing investors to lock in a higher rate of income from a historically reliable payer. The dividend also appears secure: Abbott’s payout ratio is roughly 68% of earnings and about 37% of cash flow, indicating the company generates more than enough cash to cover dividend payments with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott seems disconnected from the business reality. Temporary headwinds in a single division and broader sector rotation have depressed the stock price, yet Abbott’s fundamental growth engines are accelerating. Its dominant Medical Devices franchise continues to deliver, the dividend remains a bedrock of reliability, and catalysts like the Exact Sciences acquisition could add significant long-term growth. For investors with a multi-year perspective, the current valuation highlights a gap between market price and intrinsic value that merits serious consideration. |
0 Response to "We're excited to have you on board"
Post a Comment